about
Control of cell cycle progression by c-Jun is p53 dependentThe transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progressionILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cellsSNEV overexpression extends the life span of human endothelial cellsDeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cellsThe Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer riskStructure and chromosomal assignment of the mouse fra-1 gene, and its exclusion as a candidate gene for oc (osteosclerosis)Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse.Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/ MALDI-TOF/TOF and data validation by routine clinical assays.Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes.Polymorphisms of VEGF and VEGF receptors are associated with the occurrence of ovarian hyperstimulation syndrome (OHSS)-a retrospective case-control study.Association of the G473A polymorphism and expression of lysyl oxidase with breast cancer risk and survival in European women: a hospital-based case-control studyInterleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progressionAnnexin A1 attenuates EMT and metastatic potential in breast cancer.Potential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkers.Association of the rs1346044 Polymorphism of the Werner Syndrome Gene RECQL2 with Increased Risk and Premature Onset of Breast Cancer.The L10P polymorphism and serum levels of transforming growth factor β1 in human breast cancer.Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells.Analysis of the rs10046 polymorphism of aromatase (CYP19) in premenopausal onset of human breast cancer.The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity.c-Jun-dependent CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agentsEntamoeba histolytica: response of the parasite to metronidazole challenge on the levels of mRNA and protein expression.Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 geneRegulation of cancer cell migration and bone metastasis by RANKL.Protective role of Raf-1 in Salmonella-induced macrophage apoptosis.Interleukin-1 system and sex steroid receptor gene expression in human endometrial cancer.MKK7 couples stress signalling to G2/M cell-cycle progression and cellular senescence.Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions: free IGF-II is correlated with breast cancer size.Enrichment of low-abundant serum proteins by albumin/immunoglobulin G immunoaffinity depletion under partly denaturing conditions.Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer.New approaches for breast cancer: should Ret kinase be considered as a novel therapeutic target?JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development.Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.Can osteoclasts be excluded? (Reply)Regulation of dendritic cell differentiation and subset distribution by the zinc finger protein CTCFAssociation of the SNP285 and SNP309 Genetic Variants with the Risk, Age at Onset and Prognosis of Breast Cancer in Central European Women: A Hospital-Based Case-Control StudyPrognostic relevance of hypoxia inducible factor-1alpha expression in patients with melanoma
P50
Q24607483-1FC21818-2343-4A5C-ABC3-9736561215ACQ24609844-F92675DE-57E1-4420-9575-1392659AB2E1Q28262414-DC49374F-E202-41AA-B46A-11DEBCC96A83Q28289478-21ADA55F-C641-4B8D-AE38-5FE916BDB1A6Q28304564-2969A069-146F-4A56-8496-F1545610F826Q28484331-DA9FBB86-6277-4880-B1D3-9E0A29B86EE9Q28506175-23E34F6E-DD45-40EB-AE5E-C2F1138A8441Q30499924-BC6FEE05-97EB-4830-8A5E-6CF3D4CC6836Q30810923-EDF55974-1C2E-4E49-98BA-97EFFCFCBA98Q33197912-1A4B6D6D-6D85-4D49-A609-1BCB037177C2Q33645770-0DA32BF6-8DD7-4543-AC45-EA3F738461E4Q34070903-2CF6CBA4-0E0A-4FA1-ABA1-2C2C618330DFQ34999819-8A62506D-E46E-491B-B5D0-83D465E05F2DQ36039344-026A7A25-3B64-4A82-BFB5-F1B3287F7FADQ36295062-4D8DF420-587E-4BAA-8DBE-8039CDA9533DQ36404268-619E108F-E5BF-4AD2-97F3-C08AF3507B71Q37139034-6430594D-B220-4A6C-BE48-4CB492C92FFEQ37236899-271517B9-95C1-4E1F-AACB-92DACD0AF519Q37535511-FA9DF2C5-9208-47B4-AAD9-926700073A9DQ38301987-1695AD58-9582-4AF6-9461-5033D19EF8DBQ39450413-CB3F025E-A68C-4CC6-AA8B-1516362F207DQ39514940-184796E8-BB61-4F50-B1EF-C6081E03E061Q39645041-8F12C159-DC4E-481E-95E3-012C2C26CF87Q40298349-9F0900D2-217A-40EF-A606-629B4D5B25E4Q42947485-E49FCC6C-61F2-4A00-8C2A-ECB7BDEFB7C8Q44019116-D289B4B3-331C-4D8C-AFE8-C4EB3C5F8005Q44811450-00E5720F-9306-4D1B-8ABF-DF3017942318Q44951965-8754B006-33B2-4EA4-92D7-6DB8EE8257B2Q46560898-7F989FC9-732B-4BE1-8F1F-5138C9253A86Q48179087-25BF0848-A2D9-4A24-A352-6BFAD1A09A24Q48986806-18625A28-35F2-4B8A-9948-356C77495548Q54105156-6F789B9C-869E-478B-9A44-3A11B0A74CEFQ54628922-A7F5E02E-AD5E-4E9C-9CEA-25EA246DDF65Q57184580-DC604A0B-B2FD-44B3-987F-1425A5829D50Q58617311-43341DEC-B8C7-42A1-884C-77895A58B37BQ64275642-9322C6F5-4A62-4AE6-A263-217ED094D7B6Q82426176-662A5C41-A581-4ACB-A886-F9BFA5507BC7
P50
description
researcher ORCID ID = 0000-0003-1102-7789
@en
wetenschapper
@nl
name
Martin Schreiber
@ast
Martin Schreiber
@en
Martin Schreiber
@es
Martin Schreiber
@nl
type
label
Martin Schreiber
@ast
Martin Schreiber
@en
Martin Schreiber
@es
Martin Schreiber
@nl
prefLabel
Martin Schreiber
@ast
Martin Schreiber
@en
Martin Schreiber
@es
Martin Schreiber
@nl
P106
P31
P496
0000-0003-1102-7789